CUBE vs IMRX · P/E 25, rev $1.07B vs $124.2M cap
CubeSmart (CUBE) versus Immuneering Corp (IMRX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. IMRX currently screens at market cap $124.2M.
Not investment advice. Open the CUBE and IMRX stock pages for the full models.
Not investment advice.